NVSEF - IPO Update: Annexon Proposes IPO Terms
Quick Take
Annexon (ANNX) intends to raise $150 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is developing treatments for autoimmune and neurodegenerative conditions.
ANNX is pursuing multiple treatment programs with primarily one candidate.
For life science investors with a patient hold time frame, the IPO may be worth considering.
Company & Technology
South San Francisco, California-based Annexon was founded to advance a pipeline of antibody treatments for diseases such as Guillain-Barre Syndrome [GBS] and Huntington's Disease.
Management is headed by